The Coast to Coast Seminar is an hour-long presentation given on a scientific topic and made accessible to audiences at a number of remote sites through collaboration technology. C2C seminars are held every two weeks throughout the academic year alternating between the West Coast and the East Coast of Canada.
The topic of the Fall 2014 C2C seminar series is "Deep Sequencing Antibody and T-cell Receptor Repertoires for the Study of Infectious and Autoimmune Disease, and Development of Vaccines and Therapeutics".
This Fall 2014 Coast to Coast Seminar Series will examine an immediate and pressing “Big Data” problem faced by researchers examining the immune response to infectious and autoimmune diseases, and those developing vaccines and therapeutic antibodies. The series is partly motivated by a specific middleware prototype that The IRMACS Centre is developing called iReceptor, supported by a CANARIE contract. More importantly, the proposed series will be an important opportunity to help integrate the Canadian and greater international community that is grappling with this Big Data problem.
Only a few years ago, a researcher attempting to characterize the human immune response would have been able to sequence only a few hundred Antibody/B-cell receptor or T-cell receptor sequences per patient. This sequencing might have been conducted as part of research on infectious (e.g., flu, HIV) or autoimmune diseases (e.g., Multiple Sclerosis, Type 1 Diabetes), or during the development of vaccines or therapeutic antibodies. However, with the application of “deep sequencing” or “next generation sequencing” (NGS) techniques, it is now possible to sequence millions of these sequences per individual, per time point (e.g., early or late in infection, before or after vaccination), and from different sets of cells within the body. This is a prime example of the challenge of “Big Data.” In order to optimize the utility of these data for biomedical research and patient care, it will be critical to store, share and compare these huge databases. At present there is no integrated system to easily conduct these comparisons. Such a system will have to present a common data format, for both the sequence data and the sample metadata such as ethnicity, genetic background, treatment regime, gene expression, and clinical outcome, to highlight just some of the supporting data. The ability to share and compare these data is critical to using them optimally for biomedical research and patient care, and will involve significant hurdles in terms of ethics and consent, confidentiality and data security, intellectual property. This is the purpose of the workshops that are being organized in Vancouver, and a Coast to Coast seminar series addressing this topic will help to integrate the Canadian and greater international community as one step in this initiative.
Please contact us at email@example.com if you want to attend one of these seminars.
The first lecture in the series will be broadcast on September 30, 2014
Details can be found at http://www.irmacs.sfu.ca/events/coast-coast-seminars.
Dr George Georgiou, Institute for Cell and Molecular Biology, University of Texas, Austin
Antibodies comprise the effector arm of humoral immunity in humans and thus play a central and essential role in protection against disease. It is straightforward to detect whether an individual has developed a (polyclonal) antibody response to a pathogen or disease agent. However, until now, more than 100 years since the discovery of antibodies, it had not been possible to determine the identities, relative concentrations and functional characteristics of the individual antibodies that comprise the polyclonal response in serum and secretions.
We recently developed a suite of: (i) proteomic, (ii) informatic, (iii) single cell sequencing and (iv) high throughput protein structure-function analysis technologies that has now enabled the deconvolution of the polyclonal antibody pool in biological fluids. These technologies are helping delineate the relationships between steady state antibody production (serological memory) and B cell stimulation/differentiation processes in human health and disease. Novel insights on how vaccines (e.g. tetanus, seasonal flu etc) induce long term protection against pathogen challenge will be discussed.
Dr. George Georgiou is a Cockrell Family Regents Chair in Engineering #9 at the University of Texas, Austin. He is also the head of the Laboratory of Protein Therapeutics and Applied Immunology, which since 2009 has been focused on the discovery and development of protein therapeutics and on the analysis of adaptive immune responses. Dr. Georgiou's current projects include Engineering and preclinical/clinical development of human enzyme therapeutics for the treatment of solid tumors and leukemias; Development of methods for the molecular-level identification of the human antibody repertoire in blood and in secretions, and Analysis of the antibody repertoire elicited by viral infection (e.g. HIV-1) and vaccination to aid the development of more efficient vaccination strategies, among others. Earlier work by the Georgiou lab focused on redox homeostasis and protein biogenesis in bacteria and on the development of platform technologies for protein expression and engineering. These studies led to a number of mechanistic advances that are being used commercially for therapeutic protein manufacturing and protein engineering.
Mr Jacob Glanville, Chief Science Officer, Distributed Bio, Seattle
Dr Andrew Bradbury, Group Leader, Advanced Measurement Science, Los Alamos National Laboratory
Dr Jamie Scott, Tier 1 Canada Research Chair in Molecular Immunity, Simon Fraser University